CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers.
paper
Cited
Public
- Authors
- Chenoweth, Meghan J; O'Loughlin, Jennifer; Sylvestre, Marie-Pierre; Tyndale, Rachel F
- Year
- 2013
- Journal
- Pharmacogenetics and genomics
- PMID
- 23462429
- DOI
- 10.1097/FPC.0b013e32835f834d
- PMCID
- PMC3744214
Variation in the CYP2A6 gene, which decreases the rate of nicotine metabolic inactivation, is associated with higher adult smoking cessation rates during clinical trials. We hypothesized that slow metabolism is associated with increased quitting during adolescence. White adolescent smokers (N=308, aged 12-17, 36.3% male) from a cohort study were genotyped for CYP2A6, resulting in 7.8% slow, 14.0% intermediate and 78.2% normal metabolizers. Overall, 144 smokers quit smoking, as indicated by being abstinent for at least 12 months. In logistic regression analyses, the odds ratio for quitting was 2.25 (95% confidence interval 1.05, 4.80; P=0.037) for slow metabolizers relative to normal metabolizers. A linear trend toward increased quitting with decreasing CYP2A6 activity was also observed (odds ratio=1.44, 95% confidence interval 1.02, 2.01; P=0.034). Thus, CYP2A6 slow metabolism is associated with increased adolescent smoking cessation, indicating that even early in the smoking history, genetic variation is influencing smoking cessation.
Association between CYP2A6 metabolic group and quitting smoking for at least 12 months in adolescenceThree hundred and eight adolescent Caucasian smokers who were genotyped for CYP2A6 variant alleles were grouped according to projected CYP2A6 metabolic activity: CYP2A6 normal metabolizers, CYP2A6 intermediate metabolizers, and CYP2A6 slow metabolizers. A) The proportion in each CYP2A6 metabolic group that quit smoking is shown as a percentage of the total for that CYP2A6 metabolic group. B) The likelihood of quitting smoking for at least 12 months by CYP2A6 intermediate metabolizers and CYP2A6 slow metabolizers relative to CYP2A6 normal metabolizers is shown as odds ratios with 95% confidence intervals. No covariates were used in the model. * Indicates P = 0.037.
1–15 of 15
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| CYP2A6 metabolism in the development of smoking behaviors in young adults. | 2018 | 28032407 |
| The Genetics, Neurogenetics and Pharmacogenetics of Addiction. | 2014 | 25045619 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A phenome-wide association study of genetically determined nicotine metabolism reveals novel links with health-related outcomes. | Buchwald J et al. | — | 2025 | → |
| Effect of very low nicotine content cigarettes on smoking behavior in Chinese smokers with genotype-stratified nicotine metabolism rates. | Ma W et al. | — | 2025 | → |
| Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community. | Wichman ML et al. | — | 2025 | → |
| Association of monoaminergic gene polymorphisms in chronic inflammatory pulmonary disease patients with successful smoking cessation. | Mikaczo A et al. | — | 2024 | → |
| Catecholamine levels with use of electronic and combustible cigarettes. | Poudel R et al. | — | 2024 | → |
| Drug Metabolizing Enzymes: An Exclusive Guide into Latest Research in Pharmaco-genetic Dynamics in Arab Countries. | Eitan LA et al. | — | 2024 | → |
| Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients. | Puszkiel A et al. | — | 2024 | → |
| PharmVar GeneFocus: CYP2A6. | Langlois AWR et al. | — | 2024 | → |
| The Role of Nicotine Metabolic Rate on Nicotine Dependence and Rewarding: Nicotine Metabolism in Chinese Male Smokers and Male Mice. | Liu M et al. | — | 2024 | → |
| Effects of Genetic Variants in the Nicotine Metabolism Pathway on Smoking Cessation. | Li H et al. | — | 2022 | → |
| Genetic influences impacting nicotine use and abuse during adolescence: Insights from human and rodent studies. | Goldberg LR et al. | — | 2022 | → |
| Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review. | Jones SK et al. | — | 2022 | → |
| The Promise of Polygenic Risk Prediction in Smoking Cessation: Evidence From Two Treatment Trials. | Bray M et al. | — | 2022 | → |
| Impact of CYP2A6 Activity on Nicotine Reinforcement and Cue-Reactivity in Daily Smokers. | Butler K et al. | — | 2021 | → |
| Predictors of Cigarette Smoking Cessation in Adolescents: A Systematic Review. | Vallata A et al. | — | 2021 | → |
| An update on the role of common genetic variation underlying substance use disorders. | Johnson EC et al. | — | 2020 | → |
| Bidirectional Associations among Nicotine and Tobacco Smoke, NeuroHIV, and Antiretroviral Therapy. | Ghura S et al. | — | 2020 | → |
| Dissecting the genetic overlap of smoking behaviors, lung cancer, and chronic obstructive pulmonary disease: A focus on nicotinic receptors and nicotine metabolizing enzyme. | Bray MJ et al. | — | 2020 | → |
| Postnatal Smoke Exposure Further Increases the Hepatic Nicotine Metabolism in Prenatally Smoke Exposed Male Offspring and Is Linked with Aberrant <i>Cyp2a5</i> Methylation. | Lkhagvadorj K et al. | — | 2020 | → |
| Brief Report: Rate of Nicotine Metabolism and Tobacco Use Among Persons With HIV: Implications for Treatment and Research. | Schnoll RA et al. | — | 2019 | → |
| The effect of body mass index on smoking behaviour and nicotine metabolism: a Mendelian randomization study. | Taylor AE et al. | — | 2019 | → |
| The neurobiology of addiction. | Uhl GR et al. | — | 2019 | → |
| CYP2A6 metabolism in the development of smoking behaviors in young adults. | Olfson E et al. | — | 2018 | → |
| Influence of Nicotine Metabolism Ratio on [11C]-(+)-PHNO PET Binding in Tobacco Smokers. | Di Ciano P et al. | — | 2018 | → |
| Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism. | Tanner JA et al. | — | 2018 | → |
| Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. | Bierut LJ et al. | — | 2018 | → |
| Status and Future Directions of Preclinical Behavioral Pharmacology in Tobacco Regulatory Science. | LeSage MG et al. | — | 2018 | → |
| Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment. | Bozinoff N et al. | — | 2018 | → |
| Using Phytochemicals to Investigate the Activation of Nicotine Detoxification via Upregulation of CYP2A6 in Animal Models Exposed Tobacco Smoke Condensate by Intratracheal Instillation. | Lee D et al. | — | 2018 | → |
| CYP2A6 Genetic Variation Alters Striatal-Cingulate Circuits, Network Hubs, and Executive Processing in Smokers. | Li S et al. | — | 2017 | → |
| Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. | López-Flores LA et al. | — | 2017 | → |
| Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. | Taghavi T et al. | — | 2017 | → |
| Interaction between cytochrome P450 2A6 and Catechol-O-Methyltransferase genes and their association with smoking risk in young men. | Ou WC et al. | — | 2017 | → |
| Pharmacogenetic Optimization of Smoking Cessation Treatment. | Chenoweth MJ et al. | — | 2017 | → |
| Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not? | Kranzler HR et al. | — | 2017 | → |
| Variation in CYP2A6 Activity and Personalized Medicine. | Tanner JA et al. | — | 2017 | → |
| Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. | Tanner JA et al. | — | 2017 | → |
| Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting. | Fogli S et al. | — | 2016 | → |
| Associations of cytochrome P450 oxidoreductase genetic polymorphisms with smoking cessation in a Chinese population. | Li H et al. | — | 2016 | → |
| CYP2A6 Longitudinal Effects in Young Smokers. | Cannon DS et al. | — | 2016 | → |
| Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity. | Benowitz NL et al. | — | 2016 | → |
| Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. | Chan J et al. | — | 2016 | → |
| To quit or not: Vulnerability of women to smoking tobacco. | Park SJ et al. | — | 2016 | → |
| Variation in CYP2A6 and tobacco dependence throughout adolescence and in young adult smokers. | Chenoweth MJ et al. | — | 2016 | → |
| What does addiction medicine expect from neuroscience? From genes and neurons to treatment responses. | Le Foll B | — | 2016 | → |
| A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism. | Loukola A et al. | — | 2015 | → |
| Association of CYP2A6 gene polymorphisms with cigarette consumption: a meta-analysis. | Pan L et al. | — | 2015 | → |
| Cohort Profile: The Nicotine Dependence in Teens (NDIT) Study. | O'Loughlin J et al. | — | 2015 | → |
| Pharmacogenetics of nicotine and associated smoking behaviors. | Tanner JA et al. | — | 2015 | → |
| State-of-the-art office-based interventions to eliminate youth tobacco use: the past decade. | Pbert L et al. | — | 2015 | → |
| Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers. | Hamilton DA et al. | — | 2015 | → |
| Genetic polymorphisms in metabolizing enzymes modifying the association between smoking and inflammatory bowel diseases. | Ananthakrishnan AN et al. | — | 2014 | → |
| The Genetics, Neurogenetics and Pharmacogenetics of Addiction. | Demers CH et al. | — | 2014 | → |
| Pharmacogenetics of chronic obstructive pulmonary disease. | Hizawa N | — | 2013 | → |